SOHO 2021 | The future of treating pediatric ALL with CAR-T
Stephan Grupp, MD, PhD, of the Children’s Hospital of Philadelphia, Philadelphia, PA, discusses issues in treating pediatric acute lymphoblastic leukemia (ALL) with chimeric antigen receptor (CAR) T-cell therapy. Since its FDA approval, the first-generation cellular therapy tisagenlecleucel continues to be widely used, however, its access beyond First World countries continues to be an issue that needs to be addressed in the future. CD19 escape is another issue that needs to be addressed as well as how best to prolong remission rates with the use of dual-targeted therapies. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Stephan Grupp, MD, PhD, has participated in consultancy work with and received research support from Novartis.
